An evaluation of patients’ adherence with hypoglycemic medications among Papua New Guineans with Type 2 Diabetes:  Influencing factors by Pihau-Tulo, Stella et al.
© 2014 Pihau-Tulo et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Patient Preference and Adherence 2014:8 1229–1237
Patient Preference and Adherence Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1229
O r i g i n A l  r e s e A r c h
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/PPA.S66655
An evaluation of patients’ adherence with 
hypoglycemic medications among Papua new 




chiri and school of Pharmacy,  
curtin University, Perth, WA, Australia
correspondence: Jeffery D hughes 
school of Pharmacy, curtin University, 
gPO Box U1987, Perth, WA 6845, 
Australia 
Tel +61 8 9266 7367 
Fax +61 8 9266 2769 
email j.d.hughes@curtin.edu.au 
Purpose: The aims of this study were to evaluate the extent of adherence to hypoglycemic 
medications, assess the relationship between adherence and glycemic control, and evaluate 
factors affecting adherence.
Research design and methods: This was a cross-sectional study of patients with established 
type 2 diabetes attending the Port Moresby General Hospital Diabetes Clinic. Face-to-face 
interviews were conducted using a questionnaire designed for the study and data were collected 
concerning the 3 months prior to interview. The questionnaire covered demographic details, 
lifestyle, biochemical and physical measurements, and medication management. Glycemic 
control was investigated among patients adhering to their medications (not missing doses) to 
different degrees (100%, 95%, 90%, and 80%). 
Results: Of a total of 356 participants who were prescribed hypoglycemic medications, 59.6% 
omitted some of their doses. Age appeared to have a significant impact on adherence at some 
levels of adherence, with those aged 60 years being more likely to be adherent (logistic 
regression). Those who were 95%–99% and those who were 80% adherent had a statistically 
significant risk of a high glycated hemoglobin of 10% (85.5 mmol/mol). Multiple factors were 
identified as contributors to nonadherence, with patient-based issues (86.0%) and the health 
care system (21.7%) being the most common.
Conclusion: This study showed a significant level of nonadherence among patients with 
type 2 diabetes in Papua New Guinea. Nonadherence to medication appeared to be associated 
with poor glycemic control and was due to a variety of reasons. Future interventions aimed at 
improving adherence will need to take these into account.
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Introduction
The World Health Organization (WHO) reports that there are 347 million people 
living with diabetes worldwide and, of these, more than 80% live in low- and middle-
income countries.1
Papua New Guinea (PNG) is a lower-middle-income country where diabetes 
is increasing. The earliest report of diabetes in PNG was in 1963, where 10 cases 
were seen at the Port Moresby General Hospital (PMGH) over a 3-year period.2 
The first survey of diabetes in 1962 found no cases in a rural district and a 0.2% 
prevalence in four suburban communities in Port Moresby.3 The diabetes prevalence 
in various coastal population groups in PNG have been reported to range from 0.2% 
in the 1960s to 33.0% in the 1990s.3–7 A survey in two highlands populations in 
1983 and 1985 reported a complete absence of diabetes as well as impaired glu-
cose tolerance prevalence rates ranging from 1.7%–2.7%.6,8 The WHO reported 
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in 2000 that PNG had 152,000 cases of diabetes,9 while 
the International Diabetes Federation in 2013 reported 
the number of cases to be 203,000.10 Furthermore, the 
WHO has estimated that the number of cases of diabetes 
will increase to 392,000 by 2030.9 PNG has a population 
of 7 million and the national prevalence of diabetes in 
adults aged 20–79 year reported by International Diabetes 
Federation in 2013 was 5.4%.10
The increasing prevalence of type 2 diabetes in PNG will 
lead to a significant economic burden because of increased 
health care costs incurred from hospitalizations and associ-
ated costs, clinic visits, and use of medicines, not only for 
persistent hyperglycemia but also for complications of dia-
betes. Poor self-management of drug therapy by patients with 
diabetes may worsen the burden of diabetes in PNG. 
Studies linking glycemic control, hypoglycemic 
medications, and complications of diabetes have shown that 
good glycemic control is important in preventing microvas-
cular complications of this condition.11–13 A study in PNG 
showed that, over a 1-year period, 64% of the 83 patients 
with diabetes showed poor glycemic control (glycated hemo-
globin [A1C] 10.0% [85.8 mmol/mol]).14 To the best of 
our knowledge, no recent studies have been published on 
glycemic control among Papua New Guineans with type 2 
diabetes.
One of the challenges in achieving good glycemic control 
is patients’ nonadherence to their medications. Nonadher-
ence to medications for chronic diseases such as diabetes is 
a complicated and dynamic problem that can seriously affect 
patient outcomes. 
Using different definitions and methodologies to assess 
medication adherence, studies have reported adherence rates 
to oral hypoglycemic medications ranging from 36%–93% in 
patients with type 2 diabetes.15–19 A number of studies have 
reported different factors that contribute to nonadherence 
with hypoglycemic medications.
Many other studies have reported medication adherence 
challenges in different countries or populations; however, 
this is the first study that investigates the issue in PNG 
specifically.
The consequences of diabetes in a vulnerable country 
like PNG are expected to be devastating in their demand 
on the health care system. Even at present, the PNG health 
care system does not have sufficient resources to provide 
adequate support to patients with diabetes and other chronic 
illnesses. In the future, the health services are expected to 
be pushed well beyond capacity to deal with this emerging 
epidemic.






All patients who were diagnosed with type 2 diabetes and 
were registered at the PMGH Diabetes Clinic for at least 
3 months were considered for inclusion. This ensured that 
recently diagnosed subjects were excluded from study, as 
the main outcomes concerned adherence and glucose control 
over the 3 months leading up to enrollment in the study. All 
patients in the appointment book were identified as poten-
tially eligible participants. The registration book was used 
to confirm date of diagnosis.
Patients diagnosed with HIV/AIDS, pregnant women, and 
those using a wheelchair were excluded from the study. Those 
requiring a wheelchair were excluded because the broader 
study required physical measurements that were difficult to 
obtain for these patients. Eligible patients were informed of 
the study and invited to participate; those who agreed to do 
so provided written informed consent.
Data collection
The survey tool used was developed from the WHO STEP-
wise approach to Surveillance of non-communicable diseases 
(STEPS) instrument.20 Questions on medication were spe-
cifically included as well as details such as: year of diabetes 
diagnosis; initial management of diabetes; and management 
over the 3 months leading up to recruitment in the study. 
Questions on management of diabetes included whether or 
not the patient was put on a prescribed diet, hypoglycemic 
agent(s) and co-medications, lifestyle modifications, and any 
other forms of diabetes management.
Demographic information 
Basic demographic data included sex, age, and area of 
residence. For the purposes of this study, area of residence 
was classified as: urban, peri-urban, rural, or other province. 
The urban dwellers were those who were living in urbanized 
suburbs within the city; peri-urban were those living in partly 
urbanized villages between the city suburbs and the rural 
villages within the outskirts of the city; rural dwellers were 
those living in rural villages in the Central Province; and 
dwellers in other provinces were those who lived outside of 
the National Capital District and Central Province. 
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Medication adherence
Patients were interviewed to identify if they had missed any 
diabetic medication doses over the immediately preceding 
3-month period. The number of doses omitted for each hypo-
glycemic medication, frequency of omitting doses, and the 
reasons for omitting doses were documented. Analysis focused 
on adherence and the key factors influencing adherence. 
Glycemic control was examined at four different thresholds 
of adherence, namely 100% (complete adherence with treat-
ment), 95%, 90%, and 80%. Percentage adherence was calcu-
lated by using the number of doses used in the 3 months as the 
numerator and the total number of prescribed doses for the 3 
months as the denominator. Comments regarding the reasons 
for nonadherence were reviewed by the primary investigator 
and main themes were identified (qualitative analysis).
glycemic control
Each patient’s A1C level was measured following the 
interview using a Point-of-care Siemens/Bayer DCA 2000 
VantageTM AIC analyser (Siemens Medical Solutions USA 
Inc, Malvern, PA, USA).
ethics
Ethics approval to conduct this study was provided by the 
Curtin University Human Research Ethics Committee, the 
University of PNG, School of Medicine and Health Sciences 
Research and Ethics Committee, and the PNG Department 
of Health Medical Research Advisory Committee. Permis-
sion to undertake the study at the PMGH was granted by the 
hospital management.
Data analysis 
Data were entered into an Excel dataset (Microsoft Corpora-
tion, Redmond, WA, USA), and transferred into the SAS 
version 9.2 statistical software (SAS Institute Inc., Cary, NC, 
USA) for analysis. Simple descriptive statistics were used 
to summarize the profile of study participants. Percentages 
of patients who were classified as nonadherent to medica-
tion within each subgroup – defined by their sex, age, and 
 medication – were compared using the chi-square test, indepen-
dent sample t-test, or the Wilcoxon two-sample test as appro-
priate. Glycemic control (assessed using the level of A1C) was 
calculated and tabulated against the adherence to treatment. 
A logistic regression model was developed to identify which 
(if any) of the demographic/medical profile variables were 
independently associated with nonadherence. All the profile 
variables were initially included as covariates, then dropped, 
one at a time, until all variables remaining in the model were 
associated with adherence (backwards elimination strategy). 
Results of this regression were presented as odds ratios (ORs), 
their 95% confidence intervals (CIs), and P-values. A logistic 
regression model was also developed to assess the influence 
of different levels of adherence on the A1C measurement. 
Following convention, a P-value 0.05 was taken to indicate 
a statistically significant association in all tests.
Results
Three hundred and eighty-five patients with diabetes were 
recruited to the study. Twenty-nine of them were not taking 
any hypoglycemic medications (diet controlled only) and were 
excluded from the analysis. Among the remaining 356 partici-
pants, 144 (40.4%) reported that they did not omit any doses, 
while the remaining 212 (59.6%) reported omitting some of 
their doses. Of these 212 participants, five had ceased taking 
their medications for more than 3 months and were excluded 
from the study, and a further six could not remember how many 
doses they omitted. These six participants were included in 
the analyses of those who were known to have omitted some 
doses, as well as the analysis of the qualitative data examining 
factors contributing to omission of doses. However, they were 
excluded from analyses of those who omitted 5%, 10%, 
and 20% of doses, as their exact percentages of missing doses 
was not known. Table 1 shows the characteristics of the par-
ticipants included in the study. P-values in the table compare 
the adherence rates (complete adherence versus missing some 
doses) between different personal characteristics. The median 
(range) for: age was 55 (14–85) years; duration of disease for 
all participants was 5 (0–30) years; doses per day of all medi-
cations was four (one to 12); tablets per day was five (one to 
20); and baseline A1C was 8.7% (4.9% to 14.0%). Mean 
age appeared to differ significantly between those who adhered 
to their medications (57 years) and those who missed some 
doses (53 years, P=0.0036). The comparison of A1C between 
those who were adherent and those who were nonadherent also 
appeared to differ, whether compared in categories (Table 1) or 
comparing means (8.8% versus 9.4%, respectively, P=0.0131). 
The comparison of median A1C measurements was of bor-
derline significance (P=0.0546). The majority of participants 
were female and dwelt in urban or peri-urban areas.
A total of 345 participants were included in the analysis 
using 80%, 90%, and 95% as cut-offs for adherence, while 
351 participants were included in the analysis when adher-
ence was defined as not missing any hypoglycemic doses and 
when evaluating factors influencing adherence.
Univariate analysis of sex, area of residency, number of 
hypoglycemic agents, number of comedications,  duration 





since disease diagnosis, average number of doses, and 
 tablets per day of all medications showed that none of these 
variables appeared to be associated with adherence at any 
level. Table 2 shows the results of the multivariate logistic 
regression modeling procedure applied to the data for differ-
ent levels of adherence. Age appeared to be associated with 
adherence at some levels of adherence, with the older subjects 
(60 years) being more likely to be adherent than their 
younger counterparts. This association was not statistically 
significant for all levels of adherence, but showed a clear 
association at 100% adherence (P=0.008), and a weaker 
(P=0.035) association at 90%. A separate logistic regression 
model was used to identify any association between adher-
ence and high A1C, using A1C 10% (85.5 mmol/mol) as 
the dependent variable (Table 3). ORs for the adherence level 
were expressed relative to the completely adherent subjects. 
This analysis showed explicitly that the odds of high A1C 
was greater than 1 for all levels of nonadherence, but only 
significantly higher for the adherence levels of 95%–99% and 
80% (larger numbers of participants). Using A1C 7.0% 
(53.0 mmol/mol) as the dependent variable, those aged 
60 years tended to have poorer control than their older coun-
terparts, but this did not reach statistical significance (crude 
OR =1.62, 95% CI =0.94–2.80, P=0.084). However, those 
aged 50 years or younger were found to be twice as likely to 
have poor glycemic control compared to those aged 50 years 
or older (crude OR =2.18, 95% CI =1.19–4.01, P=0.012).
The most common reasons cited by participants for 
omitting hypoglycemic doses were patient-related issues 
(86.0%). These included forgetting doses (35.7%), patients 
not refilling prescriptions (32.4%), and patients refusing 
to take their hypoglycemic medications (10.6%). The next 
most important factors cited were health-care-system related 
(21.7%). Access to the diabetes clinic for repeat prescriptions 
was the most common issue of this type identified (15.9%, 
Table 4).
Discussion
Adherence to medications is of paramount importance 
because there are strong correlations between medica-
tion adherence, patient outcomes, and treatment costs.21–23 
Omission of medication doses is the most common type of 
 nonadherence.24 This may be intentional or unintentional. 
This study evaluated omission of hypoglycemic medications 
and investigated reasons why patients omit their doses. 
A high proportion of participants (59.6%) reported 
omitting at least some of their doses. This is consistent with 
the trends that have been reported elsewhere.15–19 Studies 
Table 1 Participant characteristics 





























































Notes: n=351. aMay not add up to the total because of missing data. bnumbers in the “nonadherent” column show the percentage of each row who were not completely 
(100%) adherent to their medications. cP-values are calculated from the chi-square statistic.
Abbreviation: A1c, glycated hemoglobin.
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have shown that nonadherence to medications leads to poor 
 glycemic control25–28 but, unlike serious conditions such as HIV 
infection, there has not been agreement on what constitutes 
clinically adequate medication adherence in type 2 diabetes. 
Many studies have used the 80% and 90% cut-off to indicate 
adequate adherence. One argument for a cut-off point of 80% 
is the observation that the rate of hospitalization increased as 
the adherence scores fell below this threshold.29 In our study, 
different cut-offs for adherence were used to determine their 
impact on glycemic control. Missing any doses appeared to be 
associated with a very high A1C measurement (A1C 10% 
[85.8 mmol/mol]). 
Sex did not appear to be associated with adherence in 
this study. This is consistent with other studies.17,30,31 Raum 
et al however, showed sex-specific differences in the asso-
ciation of adherence and poor glycemic control.32 Their 
study32 showed that there were only marginal differences in 
adherence between men and women, but nonadherent men 
carried double the risk of poor glycemic control compared 
to adherent men. Adherent and nonadherent women, how-
ever, did not differ significantly in regard to poor glycemic 
control.
Only three hypoglycemic medications are available 
through the public health care system in PNG – these are 
glibenclamide, metformin, and insulin. This number is lim-
ited because the list of medicines purchased is based on the 
WHO Model List of Essential Medicines, which is used to 
ensure affordable medicines are widely available. Usage of 
insulin in PNG is limited by requirements for its storage. As 
seen in this study, about 20% of participants live in the rural 
areas and 20% live in peri-urban areas. In rural PNG, only a 
few homes have portable electricity generators, but electricity 
is mostly for smaller appliances and lighting purposes only. 
Some peri-urban areas may not have consistent electricity 
supplies and, in particular, may not have refrigerators.
There is evidence that strong psychosocial support 
improves medication adherence.33 Participants in this study 
live in a society where extended families usually live in the 
one house. Family ties are strong and, usually, younger family 
members care for their elder relatives in the family home. 
The strong psychosocial support in a PNG society may have 
contributed to the finding that medication burden (number 
of hypoglycemic agents, number of comedications, average 
number of doses, and tablets per day of all medications) did 
Table 2 Multivariate logistic regression with nonadherence as the dependent variable

































Table 3 Logistic regression analysis: the influence of medication adherence on abnormally high A1C
Adherence level A1C 10% n/N (%)a Odds ratio 95% confidence interval P-value
100% 31/136 (22.8) 1 (reference)
95%–99% 38/92 (41.3) 2.4 1.3 to 4.2 0.0032
90%–94% 12/36 (33.3) 1.7 0.8 to 3.8 0.1970
80%–89% 6/19 (31.6) 1.6 0.5 to 4.5 0.4030
80% 19/45 (42.2) 2.5 1.2 to 5.1 0.0129
Notes: Each participant was classified into their level of adherence, and the dependent variable was high A1C (A1C 10% [85.8 mmol/mol]). aThe column showing “n/n 
(%)” shows the number of people (and percentage) within the given adherence level who have high A1c.
Abbreviation: A1c, glycated hemoglobin.





not affect adherence. However, some studies carried out in 
societies that are different to that of PNG have also found that 
a high medication burden or polytherapy may not contribute 
to medication nonadherence.25,26,30 This lack of association 
may not be consistent across all populations, as other studies 
have shown that a high medication burden is related to low 
levels of medication adherence.24,34 With the advantage of 
strong psychosocial support in PNG, patients and their fam-
ily carers may need to develop good routines in medication 
behavior as it has been shown that developing such routines 
usually leads to higher levels of adherence.33
Younger people tend to have other priorities in their lives 
and lead busier lives than the elderly, due to employment 
and other social activities. This may partly explain why the 
younger age group was less adherent to their hypoglycemic 
medications than the older age group in this study. Older 
people may have also been more adherent in this study 
population because the study setting has a medication sup-
ply policy that exempts those aged 60 years and older from 
medication fees. Furthermore, care of the elderly in a single 
household where extended family usually live in a society 
like that in PNG may have led to better adherence in those 
aged 60 years and older. This finding that older people are 
more adherent is consistent with other studies that have 
shown that better hypoglycemic medication adherence is 
associated with increased age.18,35,36 Furthermore, studies in 
societies like that in PNG, where the elderly are cared for 
in homes where extended families reside, have also shown 
that older people have better glycemic control than their 
younger counterparts.19,37,38 These results, however, differ 
from the Scottish study, which found that younger patients 
had better adherence to their hypoglycemic medications.34 
Interestingly, Nagrebetsky et al claimed that better glycemic 
control in older patients is to do with lower body mass index 
rather than good adherence.39
Our study showed that only a small number of participants 
(average of 18.3%) achieved the optimal target glycemic con-
trol of 7.0% (53.0 mmol/mol). This is slightly less than that 
seen in a Malaysian study population,40 but much less than that 
seen in Nigeria.41 A meta-analysis of data from 12 Asian coun-
tries42 showed that 45% of the populations studied had A1C 
8.0% (63.9 mmol/mol). An earlier study14 in PNG showed 
that 64% (N=83) had poor glycemic control (A1C 10.0% 
[85.8 mmol/mol]). Our study suggests that missing any 
dose has a negative impact on glycemic control, which sug-
gests that attainment of the highest possible adherence rate 
is important in this study population. Several earlier PNG 
studies have shown high morbidity and mortality associated 
with complications of diabetes;43,44 however, current studies in 
PNG in this area are lacking. Achieving good glycemic con-
trol is important to reduce such morbidities and mortalities. 
Studies in the US have shown that improved glycemic control 
is beneficial to patients with type 2 diabetes and, in general, 
conclude that every percentage point reduction in A1C can 
reduce the risk of microvascular complications such as kidney 
diseases, eye diseases, and neuropathies by 40%.45
The most common reasons cited by participants for omit-
ting doses were patient and health care-system related. The 
most common patient-related reason for omitting doses cited 
by participants was that patients forgot to take their medica-
tions. This is similar to a Hungarian study that showed that 
44.6% of participants forgot to take their medications.46 The 
next most common patient-related factor was participants 
not refilling their medications despite having prescriptions. 
This group of participants did not elaborate further on their 
reasons for not doing so.
All participants who had problems with access to the 
diabetes clinic reported that they were waiting for their next 
medical review to pick up their new prescriptions. This led to 
them not continuing their medications as required. The con-
tributing factors to this are: increase in the number of patients 
attending the clinic; scheduling of appointments; the number 
of clinic days and hours per week; cancellation/rescheduling 
of clinic times; shortage of staff at the clinic; and closure of the 
clinic from the beginning of December to the end of January 
Table 4 Identified number of factors contributing to nonadherence 






Had script but did not refill
refused to take hypoglycemic medications
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(Travel, transport costs to and from 
remote villages to the city, alternative 











Access to and from remote villages
inconsistent medical supplies in public 
hospital










Theft of bag containing medications 2 (1.0%)
Note: aTotal percentage 100% because some participants gave more than one reason.
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every year. Scheduling of review dates for each individual 
patient depends on availability of an appointment time. Even 
if a doctor wants to see a patient 1 month later, for example, 
the next available appointment may not be until 2 weeks after 
that. This may lead to a patient missing out on their medica-
tions for 2 weeks, because the doctor will usually prescribe 1 
month’s supply of medication with the understanding that the 
patient will be seen again after a month. Despite the increase 
in the number of people diagnosed with diabetes, the clinic is 
still only open for 3 hours per week. To make matters worse, 
shortage of staff (both nursing and medical) often leads to 
cancellation or scaling down of the clinic. 
Cost of medications is a crucial issue in medication 
adherence, especially for those who have been diagnosed 
with chronic diseases like type 2 diabetes, because therapy is 
ongoing (lifelong). A further cost burden is often incurred due 
to the complications associated with diabetes. Most patients 
in PNG do not have private medical insurance, but all patients 
benefit from subsidized medications through the public health 
system. Despite minimal medicine costs, many patients still 
cannot afford medications. There are also associated costs 
such as consultation fees and cost of transport to the clinic. 
Almost 20% of the participants in this study lived in rural vil-
lages where the cost of transport is even more than the cost of 
medicines. Apart from transport costs, those who live in the 
rural areas have to find accommodation in the city where the 
diabetes clinic is. Studies elsewhere have shown that cost of 
medications contributes to reduced adherence.38,41,47 The incon-
venience of travel and the cost of travel also play a role.
There are three main policies that affect access to hypo-
glycemic medications in PNG. Hypoglycemic medications are 
only available in hospitals, which makes access more expen-
sive for those living in rural villages. Another policy involves 
pharmacy fee exemptions. Patients with chronic diseases such 
as cardiovascular diseases and asthma are exempted from pay-
ing for their disease-related medications, but the same facility 
is not available in general for patients with diabetes. The excep-
tion is that patients who are 60 years and older are exempted 
from costs for all medical problems. This policy may need 
revising to improve adherence to hypoglycemic medications. 
The third policy is to do with the total quantities dispensed 
per patient. Pharmacy departments usually only dispense 
1-month’s supply, even if the prescriber makes a request for 
3-months’ supply, for example. Patients are then required to 
travel to the hospital pharmacy for their monthly refills.
There are limitations of this study method. One is that 
patients may have reported an overly optimistic estimation 
of adherence and, secondly, there may have been inaccurate 
patient recall of when and/or how many doses were missed. 
It was not possible to validate adherence through pill counts; 
however, nonadherence could be validated through extended 
duration between clinic visits. Furthermore, this study did not 
investigate the impact of hypoglycemic dosage on glycemic 
control. The generalizability of our results to other diabetes 
care facilities with limited care, such as those in PNG and 
the region in general, may be limited as this study was in a 
highly specialized setting.
Conclusion and recommendations
This study showed a significant level of nonadherence 
(59.6%) among patients with type 2 diabetes in PNG, and 
that poor adherence is associated with poor glycemic control. 
The most important predictor of adherence was found to 
be the patient’s age, with those 60 years old appearing to 
be less adherent to treatment than their older counterparts. 
However, many factors were found to contribute to nonad-
herence, with patient-based issues (86.0%) and the health 
care system (21.7%) being the most common. Therefore, 
any future interventions aimed at improving adherence will 
need to take these into account.
To improve adherence among Papua New Guineans with 
type 2 diabetes, availability of diabetes medicines at all times 
and at sites other than diabetes clinics would be extremely 
useful. In terms of health care settings, improving access 
to the diabetes clinic, which may mean a separate diabetes 
clinic instead of co-sharing with other internal medicine 
specialties, may improve medication adherence, especially 
through access to new prescriptions and longer consultation 
times when required. Furthermore, diabetes patients may 
have to be exempted from pharmacy fees, as is the case for 
patients with cardiovascular diseases and asthma. Addressing 
patient-related factors may include involving family during 
patient education sessions about medications and diabetes, or 
conducting educational and training programs outside of the 
clinic days. It would also be useful to involve those who have 
lived with diabetes for an extended duration to share their 
experiences with those who have been recently diagnosed 
with diabetes. Such programs are not currently available in 
PNG. Tools such as mobile phone reminder alarms may also 
be useful in reminding patients to take their medicines. PNG 
patients have an advantage of living in a society where the 
elderly are cared for by their extended family, which may lead 
to the development of good routines in medication behavior 
that improve medication adherence.33
Acknowledgments 
The collection of data was made possible by Dr Lloyd Ipai 
and his staff at the Diabetes Clinic, Port Moresby General 





Hospital in Papua New Guinea. We are also grateful to 
 Beulah Sipana, George Gani, and Barbara Angoro for 
 assistance in collecting data.
Disclosure
The authors report no conflicts of interest in this work. 
References 
 1. www.who.int [homepage on the Internet]. Facts and figures about 
diabetes. World Health Organization; 2011 [updated October 2013; 
cited January 9, 2014]. Available from: www.who.int/mediacentre/
factsheets/fs312/en/. Accessed December 15, 2013.
 2. Campbell CH. Diabetes Mellitus in the Territory of Papua and New 
Guinea. Med J Aust. 1963;2:607–610.
 3. Hingston RG, Price AVG. Diabetic surveys in Papua. P N G Med J. 
1964;7:33–35.
 4. Price AV, Tulloch JA. Diabetes mellitus in Papua and New Guinea. 
Med J Aust. 1966;2:645–648.
 5. Martin FI, Wyatt GB, Griew AR, Haurahelia M, Higginbottom L. 
Diabetes mellitus in urban and rural communities in Papua New 
Guinea: Studies of prevalence and plasma insulin. Diabetologia. 1980; 
18(5):369–374.
 6. King H, Finch C, Collins A, et al. Glucose tolerance in Papua New 
Guinea: ethnic differences, association with environmental and behav-
iour factors and the possible emergence of glucose intolerance in a 
highland community. Med J Aust. 1989;151(4):204–210.
 7. Dowse GK, Spark RA, Mavo B, et al. Extraordinary prevalence of 
non-insulin-dependent diabetes mellitus and bimodal plasma glucose 
distribution in the Wanigela people of Papua New Guinea. Med J Aust. 
1994;160(12):767–774.
 8. King H, Heywood P, Zimmet P, et al. Glucose tolerance in a highland 
population in Papua New Guinea. Diabetes Res. 1984;1(1):45–51.
 9. www.who.int [homepage on the Internet]. Diabetes Program. Facts 
and figures about diabetes. Country and regional data on diabetes. 
WHO Western Pacific Region, WHO Media Centre; 2014 [cited 2014 
May 20]. Available from: www.who.int/diabetes/facts/world_figures/
en/index6.html. Accessed May 20, 2014.
 10. www.idf.org [homepage on the Internet]. Diabetes facts and figures. 
International Diabetes Federation; 2014 [cited 2014 May 23]. Avail-
able from: www.idf.org/membership/wp/papua-new-guinea. Accessed 
May 20, 2014.
 11. No authors listed. Intensive blood-glucose control with sulphonylureas 
or insulin compared with conventional treatment and risk of complica-
tions in patients with type 2 diabetes (UKPDS 33). UK Prospective 
Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853.
 12. No authors listed. Effect of intensive blood-glucose control with met-
formin on complications in overweight patients with type 2 diabetes 
(UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 
1998;352(9131):854–865.
 13. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive 
blood glucose control and vascular outcomes in patients with type 2 
diabetes. N Engl J Med. 2008;358(24):2560–2572.
 14. Erasmus RT, Sinha AK. Assessment of long-term glycaemic control 
in diabetic patients attending Port Moresby General Hospital. P N G 
Med J. 1995;38(1):16–19.
 15. Cramer JA. A systematic review of adherence with medications for 
diabetes. Diabetes Care. 2004;27(5):1218–1224.
 16. Adams AS, Trinacty CM, Zhang F, et al. Medication adherence and racial 
differences in A1C Control. Diabetes Care. 2008;31(5):916–921.
 17. Jamous RM, Sweukeg WM, Abu-Taha AS, Sawalha AF, Zyoud SH, 
Morisky DE. Adherence and satisfaction with oral hypoglycemic medica-
tions: a pilot study in Palestine. Int J Clin Pharm. 2011;33:942–948.
 18. Tiv M, Viel J-F, Mauny F, et al. Medication adherence in type 2 diabe-
tes: The ENTRED Study 2007, a French population-based study. PLoS 
ONE. 2012;7(3):e32412. 
 19. Wong MC, Kong AP, So WY, Jian JY, Chan JC, Griffiths SM. Adher-
ence to oral hypoglycemic agents in 26,782 Chinese patients: a cohort 
study. J Clin Pharmacol. 2011;51(10):1474–1482.
 20. www.who.int [homepage on the internet]. Chronic diseases and health 
promotion. The STEPS Instrument and Support Materials. World Health 
Organisation; 2007 [cited January 4, 2013]. Available from: www.who.
int/chp/steps/Part5.pdf. Accessed March 9, 2010.
 21. Breitscheidel L, Stamenitis S, Dippel FW, Schoffski O. Economic 
impact of compliance to treatment with antidiabetes medication in type 
2 diabetes mellitus; a review paper. J Med Econ. 2010;13(1):8–15.
 22. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonad-
herence on hospitalisation and mortality among patients with diabetes 
mellitus. Arch Intern Med. 2006;166(17):1836–1841.
 23. Hansen RA, Farley JF, Droege M, Maciejewski ML. A retrospective 
cohort of study of economic outcomes and adherence to monotherapy 
with metformin, pioglitazone, or a sulphonylurea among patients with 
type 2 diabetes mellitus in the United States from 2003–2005. Clin 
Ther. 2010;32(7):1308–1319.
 24. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on 
patient compliance. Diabetes Care. 1997;20(10):1512–1517.
 25. van Bruggen R, Gorter K, Stolk RP, Zuithoff P, Klungel OH, Rutten GE. 
Refill adherence and polypharmacy among patients with type 2 diabetes in 
general practice. Pharmacoepidemiol Drug Saf. 2009;18(11):983–991.
 26. Kim N, Agostini JV, Justice AC. Refill adherence to oral hypoglycemic 
agents and glycemic control in veterans. Ann Pharmacother. 2010; 
44(5):800–808.
 27. Aikens JE, Piette JD. Longitudinal association between medication 
adherence and glycemic control in type 2 diabetes. Diabet Med. 2013; 
30(3):338–344.
 28. Quah JH, Liu YP, Luo N, How CH, Tay EG. Younger adult type 2 dia-
betic patients have poorer glycemic control: a cross-sectional study in a 
primary care setting in Singapore. BMC Endocr Disord. 2013;13(18).
 29. Lau DT, Nau DP. Oral antihyperglycaemic medication nonadherence 
and subsequent hospitalisation among individuals with type 2 diabetes. 
Diabetes Care. 2004;27(9):2149–2153.
 30. Haupt D, Weitoft GR, Nilsson JL. Refill adherence to oral antihyper-
glycaemic drugs in Sweden. Acta Diabetol. 2009;46(3):203–208.
 31. Geisel-Marbaise S, Stummer H. Diabetes adherence – does gender 
matter? J Public Health. 2010;18(3):219–226.
 32. Raum E, Heike UK, Ruter G, et al. Medication nonadherence and poor 
glycaemic control in patients with type 2 diabetes mellitus. Diabetes 
Res Clin Pract. 2012;97(3):377–384.
 33. Borgsteede SD, Westerman MJ, Kok IL, Meeuse JC, de Vries TP, 
Hugtenburg JG. Factors related to high and low levels of drug adherence 
according to patients with type 2 diabetes. Int J Clin Pharm. 2011;33(5): 
779–787.
 34. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed 
oral hypoglycaemic medication in a population of patients with 
type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19(4): 
279–284.
 35. Davis-Ajami ML, Nahata MC, Reardon G, Seiber EE, Balkrishnan R. 
Associations between joblessness and oral anti-diabetic medication 
adherence in US Diabetic Working-Age adults. Health Outcomes Res 
Med. 2012;3(3):e140–e151.
 36. Patel I, Chang J, Shenolikar RA, Balkrishnan R. Medication adherence 
in low income elderly type 2 diabetes patients: a retrospective cohort 
study. Int Journal of Diabetes Mellit. 2010;2(2):122–124.
 37. Ahmad NS, Islahudin F, Paraidathathu T. Factors associated with 
good glycemic control among patients with type 2 diabetes mellitus. 
J Diabetes Invest. Epub 2013 Dec 5.
 38. Rwegerera GM. Adherence to anti-diabetic drugs among patients with 
type 2 diabetes mellitus at Muhimbili National Hospital, Dar es Salaam, 
Tanzania – A cross-sectional study. Pan Afr Med J. 2014;17:252.
 39. Nagrebetsky A, Griffin S, Kinmonth AL, Sutton S, Craven A, Farmer 
A. Predictors of suboptimal glycaemic control in type 2 diabetes: the 
role of medication adherence and body mass index in the relationship 
between glycaemia and age. Diabetes Res Clin Pract. 2012;96(2): 
119–128.
Patient Preference and Adherence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/patient-preference-and-adherence-journal
Patient Preference and Adherence is an international, peer-reviewed, 
open access journal that focuses on the growing importance of patient 
 preference and adherence throughout the therapeutic continuum. Patient 
satisfaction, acceptability, quality of life, compliance, persistence and their 
role in  developing new therapeutic modalities and compounds to optimize 
clinical  outcomes for existing disease states are major areas of interest for 
the  journal. This journal has been accepted for indexing on PubMed Central. 
The  manuscript management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit http://www.
dovepress.com/testimonials.php to read real quotes from published authors.
Dovepress




Adherence with hypoglycemic medications in Papua new guinea
 40. Al-Qazaz HKh, Sulaiman SA, Hassali MA, et al. Diabetes knowledge, 
medication adherence and glycaemic control among patients with type 
2 diabetes. Int J Clin Pharm. 2011;33(6):1028–1035.
 41. Yusuff KB, Obe O, Joseph BY. Adherence to antidiabetic therapy and 
self- management practices among type 2 diabetics in Nigeria. Pharm 
World Sci. 2008;30(6):876–883.
 42. Chuang LM, Tsai ST, Huang BY, Tai TY; Diabcare-Asia 1998 Study 
Group. The status of diabetes control in Asia- a cross-sectional survey 
of 24,317 patients with diabetes mellitus in 1998. Diabet Med. 2002; 
19(12):978–985.
 43. Martin FI. The clinical characteristics of diabetes mellitus in Papua 
New Guinea. P N G Med J. 1978;21(4):317–322.
 44. Savige J, Martin FI. Mortality and morbidity of diabetes in Papua New 
Guinea. Diabetologia. 1982;23(2):136–137.
 45. Diabetes.niddk.nih.gov [homepage on the Internet]. National Diabetes 
Statistics 2011. National Institute of Diabetes and Digestive and Kidney 
Disease. [cited 2013 December 15]. Available from: diabetes.niddk.
nih.gov/dm/pubs/statistics/DM_statistics_508.pdf. Accessed July 16, 
2013.
 46. Hankó B1, Kázmér M, Kumli P, et al. Self-reported medication and 
lifestyle adherence in Hungarian patients with type 2 diabetes. Pharm 
World Sci. 2007;29(2):58–66.
47. Sankar UV, Lipska K, Mini GK, Sarma PS, Thankappan KR. The 
adherence to medications in diabetic patients in rural Kerala, India. 
Asia Pac J Public Health. Epub 2013 Feb 14. 
